Biosimulation Market by Product (Software, Molecular Simulation, In House, Contract Services), Application (Clinical Trials, PKPD, ADME), Delivery (Subscription, Ownership), End User (Biotech, Pharma Companies, CROs, Regulatory) - Global Forecast to 2022
“Global biosimulation market projected to grow at a CAGR of 15.9%”
The biosimulation market is expected to reach USD 2.88 billion by 2022 from USD 1.38 billion in 2017, at a CAGR of 15.9%. Increase in R&D investments in the pharmaceutical and biotechnology industries, growing adoption of biosimulation software by regulatory bodies, technologically advanced QSP systems, need to curtail drug discovery and development costs, and growth in the biologics and biosimilars markets are driving the growth of the biosimulation market. On the other hand, market growth may be limited to a certain extent due to the lack of standardization for biosimulation solutions.
“Biosimulation services are expected to grow at the highest CAGR during the forecast period”
By product and service, the biosimulation market is segmented into software and services. The biosimulation services segment is projected to register the highest CAGR during the forecast period. The high growth in this segment is attributed to the recurring need for services such as data analysis, and consulting services.
“Ownership models segment is expected to dominate the market during the forecast period”
Based on the delivery model, the biosimulation market is segmented into ownership models and subscription models. The ownership models segment is expected to dominate the market during the forecast period. Buyers mainly opt for these delivery models due to the security benefits associated with them are the major factors that are supporting the growth of this delivery models segment.
“Europe to witness high growth during the forecast period”
In 2017, North America is expected to account for the largest share of the market followed by Europe. However, Europe is expected to register the highest CAGR during the forecast period. The growing focus on research-related funding activities by governments is expected to assist in the development of drug discovery and development process, thus driving the demand for biosimulation in the European region.
The primary interviews conducted for this report can be categorized as follows:
The report provides an overview of the biosimulation market. It aims at estimating the market size and future growth potential of this market across different segments such as product & service, applications, delivery model, end user, and region. Furthermore, the report also includes an in-depth competitive analysis of the key players in the market along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help the market leaders/new entrants in this market by providing them with the closest approximations of revenues for the overall biosimulation market and its subsegments. This report will help stakeholders to understand the competitive landscape better and gain insights to position their businesses and help companies make suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provide them with information regarding key market drivers and opportunities.
The biosimulation market is expected to reach USD 2.88 billion by 2022 from USD 1.38 billion in 2017, at a CAGR of 15.9%. Increase in R&D investments in the pharmaceutical and biotechnology industries, growing adoption of biosimulation software by regulatory bodies, technologically advanced QSP systems, need to curtail drug discovery and development costs, and growth in the biologics and biosimilars markets are driving the growth of the biosimulation market. On the other hand, market growth may be limited to a certain extent due to the lack of standardization for biosimulation solutions.
“Biosimulation services are expected to grow at the highest CAGR during the forecast period”
By product and service, the biosimulation market is segmented into software and services. The biosimulation services segment is projected to register the highest CAGR during the forecast period. The high growth in this segment is attributed to the recurring need for services such as data analysis, and consulting services.
“Ownership models segment is expected to dominate the market during the forecast period”
Based on the delivery model, the biosimulation market is segmented into ownership models and subscription models. The ownership models segment is expected to dominate the market during the forecast period. Buyers mainly opt for these delivery models due to the security benefits associated with them are the major factors that are supporting the growth of this delivery models segment.
“Europe to witness high growth during the forecast period”
In 2017, North America is expected to account for the largest share of the market followed by Europe. However, Europe is expected to register the highest CAGR during the forecast period. The growing focus on research-related funding activities by governments is expected to assist in the development of drug discovery and development process, thus driving the demand for biosimulation in the European region.
The primary interviews conducted for this report can be categorized as follows:
- By Company Type: Tier 1 – 62%; Tier 2 - 25%; Tier 3 - 13%.
- By Designation: C-level- 29%; D-level- 25%; Others-46%.
- By Region: North America-55%; Europe-24%; Asia-15%; RoW-6%.
- Certara (US)
- Simulations Plus (US)
- Dassault Syst?mes (France)
- Schr?dinger (US)
- ACD/Labs (Canada)
- Chemical Computing Group (Canada)
- Physiomics (UK)
- Evidera (US)
- In silico biosciences (US)
- INOSIM Software (Germany)
- Insilico Biotechnology (Germany)
- LeadInvent Technologies (India)
- Rosa (US)
- Nuventra Pharma (US)
- Genedata (Switzerland)ssss
The report provides an overview of the biosimulation market. It aims at estimating the market size and future growth potential of this market across different segments such as product & service, applications, delivery model, end user, and region. Furthermore, the report also includes an in-depth competitive analysis of the key players in the market along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help the market leaders/new entrants in this market by providing them with the closest approximations of revenues for the overall biosimulation market and its subsegments. This report will help stakeholders to understand the competitive landscape better and gain insights to position their businesses and help companies make suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provide them with information regarding key market drivers and opportunities.
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 MARKET STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 SECONDARY DATA
2.2.1 SECONDARY SOURCE
2.3 PRIMARY DATA
2.3.1 PRIMARY SOURCES
2.3.2 KEY INDUSTRY INSIGHTS
2.4 MARKET SIZE ESTIMATION
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
2.6 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 BIOSIMULATION MARKET OVERVIEW
4.2 BIOSIMULATION SOFTWARE MARKET, BY TYPE
4.3 GEOGRAPHIC ANALYSIS: BIOSIMULATION MARKET IN EUROPE, BY END USER AND COUNTRY
4.4 BIOSIMULATION DRUG DEVELOPEMENT MARKET, BY TYPE
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increase in R&D investments in the pharmaceutical and biotechnology industries
5.2.1.2 Growing adoption of biosimulation software by regulatory bodies
5.2.1.3 Technologically advanced QSP systems
5.2.1.4 Need to curtail drug discovery and development costs
5.2.1.5 Growth in the biologics and biosimilars markets
5.2.2 RESTRAINT
5.2.2.1 Lack of standardization
5.2.3 OPPORTUNITIES
5.2.3.1 Emerging applications
5.2.3.2 Increased use of personalized medicine
5.2.3.3 Use of biosimulation solution for pediatric drug development
5.2.4 CHALLENGES
5.2.4.1 Difficulty in matching the complexity of biological systems and processes
5.2.4.2 Shortage of biosimulation and modeling experts
6 BIOSIMULATION MARKET, BY PRODUCT & SERVICE
6.1 INTRODUCTION
6.2 SOFTWARE
6.2.1 PK/PD MODELING AND SIMULATION SOFTWARE
6.2.2 MOLECULAR MODELING AND SIMULATION SOFTWARE
6.2.3 PBPK MODELING AND SIMULATION SOFTWARE
6.2.4 TOXICITY PREDICTION SOFTWARE
6.2.5 TRIAL DESIGN SOFTWARE
6.2.6 OTHER BIOSIMULATION SOFTWARE
6.3 SERVICES
6.3.1 IN-HOUSE SERVICES
6.3.2 CONTRACT SERVICES
7 BIOSIMULATION MARKET, BY APPLICATION
7.1 INTRODUCTION
7.2 DRUG DEVELOPMENT
7.2.1 PRECLINICAL TESTING
7.2.1.1 PK/PD
7.2.1.2 ADME/Tox
7.2.2 CLINICAL TRIALS
7.3 DRUG DISCOVERY
7.3.1 TARGET IDENTIFICATION AND VALIDATION
7.3.2 LEAD IDENTIFICATION AND OPTIMIZATION
7.4 OTHER APPLICATIONS
8 BIOSIMULATION MARKET, BY DELIVERY MODEL
8.1 INTRODUCTION
8.2 SUBSCRIPTION MODELS
8.3 OWNERSHIP MODELS
9 BIOSIMULATION MARKET, BY END USER
9.1 INTRODUCTION
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.3 RESEARCH INSTITUTES
9.4 CONTRACT RESEARCH ORGANIZATIONS
9.5 REGULATORY AUTHORITIES
9.6 OTHER END USERS
10 BIOSIMULATION MARKET, BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 US
10.2.2 CANADA
10.3 EUROPE
10.3.1 GERMANY
10.3.2 UK
10.3.3 FRANCE
10.3.4 REST OF EUROPE (ROE)
10.4 ASIA
10.5 REST OF THE WORLD (ROW)
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 MARKET RANKING ANALYSIS, 2016
11.3 COMPETITIVE SCENARIO
11.3.1 PRODUCT LAUNCHES AND APPROVALS
11.3.2 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
11.3.3 ACQUISITIONS
11.3.4 EXPANSIONS
12 COMPANY PROFILES
(Overview, Products Offered, Product Offering Scorecard, Business Strategy Scorecard, Recent Developments)*
12.1 CERTARA
12.2 SIMULATION PLUS
12.3 DASSAULT SYST?MES
12.4 SCHR?DINGER
12.5 ADVANCED CHEMISTRY DEVELOPMENT
12.6 CHEMICAL COMPUTING GROUP
12.7 ROSA
12.8 GENEDATA
12.9 PHYSIOMICS
12.10 EVIDERA
12.11 IN SILICO BIOSCIENCES
12.12 LEADINVENT TECHNOLOGIES
12.13 INOSIM SOFTWARE
12.14 NUVENTRA PHARMA
12.15 INSILICO BIOTECHNOLOGY
*Details on MarketsandMarkets view, Overview, Products Offered, Product Offering Scorecard, Business Strategy Scorecard, and Recent Developments might not be captured in case of unlisted companies.
13 APPENDIX
13.1 INSIGHTS FORM INDUSTRY EXPERTS
13.2 DISCUSSION GUIDE
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
13.5 AVAILABLE CUSTOMIZATIONS
13.6 RELATED REPORTS
13.7 AUTHOR DETAILS
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 MARKET STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 SECONDARY DATA
2.2.1 SECONDARY SOURCE
2.3 PRIMARY DATA
2.3.1 PRIMARY SOURCES
2.3.2 KEY INDUSTRY INSIGHTS
2.4 MARKET SIZE ESTIMATION
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
2.6 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 BIOSIMULATION MARKET OVERVIEW
4.2 BIOSIMULATION SOFTWARE MARKET, BY TYPE
4.3 GEOGRAPHIC ANALYSIS: BIOSIMULATION MARKET IN EUROPE, BY END USER AND COUNTRY
4.4 BIOSIMULATION DRUG DEVELOPEMENT MARKET, BY TYPE
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increase in R&D investments in the pharmaceutical and biotechnology industries
5.2.1.2 Growing adoption of biosimulation software by regulatory bodies
5.2.1.3 Technologically advanced QSP systems
5.2.1.4 Need to curtail drug discovery and development costs
5.2.1.5 Growth in the biologics and biosimilars markets
5.2.2 RESTRAINT
5.2.2.1 Lack of standardization
5.2.3 OPPORTUNITIES
5.2.3.1 Emerging applications
5.2.3.2 Increased use of personalized medicine
5.2.3.3 Use of biosimulation solution for pediatric drug development
5.2.4 CHALLENGES
5.2.4.1 Difficulty in matching the complexity of biological systems and processes
5.2.4.2 Shortage of biosimulation and modeling experts
6 BIOSIMULATION MARKET, BY PRODUCT & SERVICE
6.1 INTRODUCTION
6.2 SOFTWARE
6.2.1 PK/PD MODELING AND SIMULATION SOFTWARE
6.2.2 MOLECULAR MODELING AND SIMULATION SOFTWARE
6.2.3 PBPK MODELING AND SIMULATION SOFTWARE
6.2.4 TOXICITY PREDICTION SOFTWARE
6.2.5 TRIAL DESIGN SOFTWARE
6.2.6 OTHER BIOSIMULATION SOFTWARE
6.3 SERVICES
6.3.1 IN-HOUSE SERVICES
6.3.2 CONTRACT SERVICES
7 BIOSIMULATION MARKET, BY APPLICATION
7.1 INTRODUCTION
7.2 DRUG DEVELOPMENT
7.2.1 PRECLINICAL TESTING
7.2.1.1 PK/PD
7.2.1.2 ADME/Tox
7.2.2 CLINICAL TRIALS
7.3 DRUG DISCOVERY
7.3.1 TARGET IDENTIFICATION AND VALIDATION
7.3.2 LEAD IDENTIFICATION AND OPTIMIZATION
7.4 OTHER APPLICATIONS
8 BIOSIMULATION MARKET, BY DELIVERY MODEL
8.1 INTRODUCTION
8.2 SUBSCRIPTION MODELS
8.3 OWNERSHIP MODELS
9 BIOSIMULATION MARKET, BY END USER
9.1 INTRODUCTION
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.3 RESEARCH INSTITUTES
9.4 CONTRACT RESEARCH ORGANIZATIONS
9.5 REGULATORY AUTHORITIES
9.6 OTHER END USERS
10 BIOSIMULATION MARKET, BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 US
10.2.2 CANADA
10.3 EUROPE
10.3.1 GERMANY
10.3.2 UK
10.3.3 FRANCE
10.3.4 REST OF EUROPE (ROE)
10.4 ASIA
10.5 REST OF THE WORLD (ROW)
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 MARKET RANKING ANALYSIS, 2016
11.3 COMPETITIVE SCENARIO
11.3.1 PRODUCT LAUNCHES AND APPROVALS
11.3.2 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
11.3.3 ACQUISITIONS
11.3.4 EXPANSIONS
12 COMPANY PROFILES
(Overview, Products Offered, Product Offering Scorecard, Business Strategy Scorecard, Recent Developments)*
12.1 CERTARA
12.2 SIMULATION PLUS
12.3 DASSAULT SYST?MES
12.4 SCHR?DINGER
12.5 ADVANCED CHEMISTRY DEVELOPMENT
12.6 CHEMICAL COMPUTING GROUP
12.7 ROSA
12.8 GENEDATA
12.9 PHYSIOMICS
12.10 EVIDERA
12.11 IN SILICO BIOSCIENCES
12.12 LEADINVENT TECHNOLOGIES
12.13 INOSIM SOFTWARE
12.14 NUVENTRA PHARMA
12.15 INSILICO BIOTECHNOLOGY
*Details on MarketsandMarkets view, Overview, Products Offered, Product Offering Scorecard, Business Strategy Scorecard, and Recent Developments might not be captured in case of unlisted companies.
13 APPENDIX
13.1 INSIGHTS FORM INDUSTRY EXPERTS
13.2 DISCUSSION GUIDE
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
13.5 AVAILABLE CUSTOMIZATIONS
13.6 RELATED REPORTS
13.7 AUTHOR DETAILS
LIST OF TABLES
Table 1 BIOSIMULATION MARKET, BY PRODUCT & SERVICE, 2015–2022 (USD MILLION)
Table 2 BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 3 BIOSIMULATION SOFTWARE MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 4 NORTH AMERICA: BIOSIMULATION SOFTWARE MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 5 EUROPE: BIOSIMULATION SOFTWARE MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 6 PK/PD MODELING AND SIMULATION SOFTWARE MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 7 NORTH AMERICA: PK/PD MODELING AND SIMULATION SOFTWARE MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 8 EUROPE: PK/PD MODELING AND SIMULATION SOFTWARE MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 9 MOLECULAR MODELING AND SIMULATION SOFTWARE MARKET, BY REGION, 2015–2022 (USD MILLION
Table 10 NORTH AMERICA: MOLECULAR MODELING AND SIMULATION SOFTWARE MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 11 EUROPE: MOLECULAR MODELING AND SIMULATION SOFTWARE MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 12 PBPK MODELING AND SIMULATION SOFTWARE MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 13 NORTH AMERICA: PBPK MODELING AND SIMULATION SOFTWARE MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 14 EUROPE: PBPK MODELING AND SIMULATION SOFTWARE MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 15 TOXICITY PREDICTION SOFTWARE MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 16 NORTH AMERICA: TOXICITY PREDICTION SOFTWARE MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 17 EUROPE: TOXICITY PREDICTION SOFTWARE MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 18 TRIAL DESIGN SOFTWARE MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 19 NORTH AMERICA: TRIAL DESIGN SOFTWARE MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 20 EUROPE: TRIAL DESIGN SOFTWARE MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 21 OTHER BIOSIMULATION SOFTWARE MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 22 NORTH AMERICA: OTHER BIOSIMULATION SOFTWARE MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 23 EUROPE: OTHER BIOSIMULATION SOFTWARE MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 24 BIOSIMULATION SERVICES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 25 BIOSIMULATION SERVICES MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 26 NORTH AMERICA: BIOSIMULATION SERVICES MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 27 EUROPE: BIOSIMULATION SERVICES MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 28 IN-HOUSE BIOSIMULATION SERVICES MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 29 NORTH AMERICA: IN-HOUSE BIOSIMULATION SERVICES MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 30 EUROPE: IN-HOUSE BIOSIMULATION SERVICES MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 31 CONTRACT BIOSIMULATION SERVICES MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 32 NORTH AMERICA: CONTRACT BIOSIMULATION SERVICES MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 33 EUROPE: CONTRACT BIOSIMULATION SERVICES MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 34 BIOSIMULATION MARKET, BY APPLICATION, 2015–2022 (USD MILLION)
Table 35 BIOSIMULATION MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2015–2022 (USD MILLION)
Table 36 BIOSIMULATION MARKET FOR DRUG DEVELOPMENT, BY REGION, 2015–2022 (USD MILLION)
Table 37 NORTH AMERICA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT, BY COUNTRY, 2015–2022 (USD MILLION)
Table 38 EUROPE: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT, BY COUNTRY, 2015–2022 (USD MILLION)
Table 39 BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2015–2022 (USD MILLION)
Table 40 BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY REGION, 2015–2022 (USD MILLION )
Table 41 NORTH AMERICA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY COUNTRY, 2015–2022 (USD MILLION)
Table 42 EUROPE: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY COUNTRY, 2015–2022 (USD MILLION)
Table 43 BIOSIMULATION MARKET FOR PK/PD, BY REGION, 2015–2022 (USD MILLION)
Table 44 NORTH AMERICA: BIOSIMULATION MARKET FOR PK/PD, BY COUNTRY, 2015–2022 (USD MILLION)
Table 45 EUROPE: BIOSIMULATION MARKET FOR PK/PD, BY COUNTRY, 2015–2022 (USD MILLION)
Table 46 BIOSIMULATION MARKET FOR ADME/TOX, BY REGION, 2015–2022 (USD MILLION)
Table 47 NORTH AMERICA: BIOSIMULATION MARKET FOR ADME/TOX, BY COUNTRY, 2015–2022 (USD MILLION)
Table 48 EUROPE: BIOSIMULATION MARKET FOR ADME/TOX, BY COUNTRY, 2015–2022 (USD MILLION)
Table 49 BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY REGION, 2015–2022 (USD MILLION)
Table 50 NORTH AMERICA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 51 EUROPE: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 52 BIOSIMULATION MARKET FOR DRUG DISCOVERY, BY TYPE, 2015–2022 (USD MILLION )
Table 53 BIOSIMULATION MARKET FOR DRUG DISCOVERY, BY REGION, 2015–2022 (USD MILLION)
Table 54 NORTH AMERICA: BIOSIMULATION MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2015–2022 (USD MILLION)
Table 55 EUROPE: BIOSIMULATION MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2015–2022 (USD MILLION)
Table 56 BIOSIMULATION MARKET FOR TARGET IDENTIFICATION AND OPTIMIZATION, BY REGION, 2015–2022 (USD MILLION)
Table 57 NORTH AMERICA: BIOSIMULATION MARKET FOR TARGET IDENTIFICATION AND VALIDATION, BY COUNTRY, 2015–2022 (USD MILLION)
Table 58 EUROPE: BIOSIMULATION MARKET FOR TARGET IDENTIFICATION AND VALIDATION, BY COUNTRY, 2015–2022 (USD MILLION)
Table 59 BIOSIMULATION MARKET FOR LEAD IDENTIFICATION AND OPTIMIZATION, BY REGION, 2015–2022 (USD MILLION)
Table 60 NORTH AMERICA: BIOSIMULATION MARKET FOR LEAD IDENTIFICATION AND OPTIMIZATION, BY COUNTRY, 2015–2022 (USD MILLION)
Table 61 EUROPE: BIOSIMULATION MARKET FOR LEAD IDENTIFICATION AND OPTIMIZATION, BY COUNTRY, 2015–2022 (USD MILLION)
Table 62 BIOSIMULATION MARKET FOR OTHER APPLICATIONS, BY REGION, 2015–2022 (USD MILLION )
Table 63 NORTH AMERICA: BIOSIMULATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 64 EUROPE: BIOSIMULATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 65 GLOBAL BIOSIMULATION MARKET, BY DELIVERY MODEL, 2015–2022 (USD MILLION)
Table 66 GLOBAL BIOSIMULATION MARKET FOR SUBSCRIPTION MODELS, BY REGION, 2015–2022 (USD MILLION)
Table 67 NORTH AMERICA: BIOSIMULATION MARKET FOR SUBSCRIPTION MODELS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 68 EUROPE: BIOSIMULATION MARKET FOR SUBSCRIPTION MODELS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 69 GLOBAL BIOSIMULATION MARKET FOR OWNERSHIP MODELS, BY REGION, 2015–2022 (USD MILLION)
Table 70 NORTH AMERICA: BIOSIMULATION MARKET FOR OWNERSHIP MODELS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 71 EUROPE: BIOSIMULATION MARKET FOR OWNERSHIP MODELS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 72 BIOSIMULATION MARKET, BY END USER, 2015–2022 (USD MILLION)
Table 73 BIOSIMULATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2015–2022 (USD MILLION)
Table 74 NORTH AMERICA: BIOSIMULATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2015–2022 (USD MILLION)
Table 75 EUROPE: BIOSIMULATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2015–2022 (USD MILLION)
Table 76 BIOSIMULATION MARKET FOR RESEARCH INSTITUTES, BY REGION, 2015–2022 (USD MILLION)
Table 77 NORTH AMERICA: BIOSIMULATION MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2015–2022 (USD MILLION)
Table 78 EUROPE: BIOSIMULATION MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2015–2022 (USD MILLION)
Table 79 BIOSIMULATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2015–2022 (USD MILLION)
Table 80 NORTH AMERICA: BIOSIMULATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 81 EUROPE: BIOSIMULATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 82 BIOSIMULATION MARKET FOR REGULATORY AUTHORITIES, BY REGION, 2015–2022 (USD MILLION)
Table 83 NORTH AMERICA: BIOSIMULATION MARKET FOR REGULATORY AUTHORITIES, BY COUNTRY, 2015–2022 (USD MILLION)
Table 84 EUROPE: BIOSIMULATION MARKET FOR REGULATORY AUTHORITIES, BY COUNTRY, 2015–2022 (USD MILLION)
Table 85 BIOSIMULATION MARKET FOR OTHER END USERS, BY REGION, 2015–2022 (USD MILLION)
Table 86 NORTH AMERICA: BIOSIMULATION MARKET FOR OTHER END USERS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 87 EUROPE: BIOSIMULATION MARKET FOR OTHER END USERS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 88 BIOSIMULATION MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 89 NORTH AMERICA BIOSIMULATION MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 90 NORTH AMERICA: BIOSIMULATION MARKET, BY PRODUCT & SERVICE, 2015–2022 (USD MILLION)
Table 91 NORTH AMERICA: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 92 NORTH AMERICA: BIOSIMULATION SERVICES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 93 NORTH AMERICA: BIOSIMULATION MARKET, BY APPLICATION, 2015–2022 (USD MILLION)
Table 94 NORTH AMERICA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2015–2022 (USD MILLION)
Table 95 NORTH AMERICA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2015–2022 (USD MILLION)
Table 96 NORTH AMERICA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2015–2022 (USD MILLION)
Table 97 NORTH AMERICA: BIOSIMULATION MARKET, BY DELIVERY MODEL, 2015–2022 (USD MILLION)
Table 98 NORTH AMERICA: BIOSIMULATION MARKET, BY END USER, 2015–2022 (USD MILLION)
Table 99 US: BIOSIMULATION MARKET, BY PRODUCT & SERVICE, 2015–2022 (USD MILLION)
Table 100 US: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 101 US: BIOSIMULATION SERVICES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 102 US: BIOSIMULATION MARKET, BY APPLICATION, 2015–2022 (USD MILLION)
Table 103 US: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2015–2022 (USD MILLION)
Table 104 US: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2015–2022 (USD MILLION)
Table 105 US: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2015–2022 (USD MILLION)
Table 106 US: BIOSIMULATION MARKET, BY DELIVERY MODEL, 2015–2022 (USD MILLION)
Table 107 US: BIOSIMULATION MARKET, BY END USER, 2015–2022 (USD MILLION)
Table 108 CANADA: BIOSIMULATION MARKET, BY PRODUCT & SERVICE, 2015–2022 (USD MILLION)
Table 109 CANADA: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 110 CANADA: BIOSIMULATION SERVICES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 111 CANADA: BIOSIMULATION MARKET, BY APPLICATION, 2015–2022 (USD MILLION)
Table 112 CANADA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2015–2022 (USD MILLION)
Table 113 CANADA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2015–2022 (USD MILLION)
Table 114 CANADA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2015–2022 (USD MILLION)
Table 115 CANADA: BIOSIMULATION MARKET, BY DELIVERY MODEL, 2015–2022 (USD MILLION)
Table 116 CANADA: BIOSIMULATION MARKET, BY END USER, 2015–2022 (USD MILLION)
Table 117 EUROPE: PHARMACEUTICAL R&D EXPENDITURE, BY COUNTRY, 2015
Table 118 EUROPE: BIOSIMULATION MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 119 EUROPE: BIOSIMULATION MARKET, BY PRODUCT & SERVICE, 2015–2022 (USD MILLION)
Table 120 EUROPE: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 121 EUROPE: BIOSIMULATION SERVICES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 122 EUROPE: BIOSIMULATION MARKET, BY APPLICATION, 2015–2022 (USD MILLION)
Table 123 EUROPE: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2015–2022 (USD MILLION)
Table 124 EUROPE: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2015–2022 (USD MILLION)
Table 125 EUROPE: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2015–2022 (USD MILLION)
Table 126 EUROPE: BIOSIMULATION MARKET, BY DELIVERY MODEL, 2015–2022 (USD MILLION)
Table 127 EUROPE: BIOSIMULATION MARKET, BY END USER, 2015–2022 (USD MILLION)
Table 128 BIOTECHNOLOGY INDUSTRY IN GERMANY (2009 VS. 2016)
Table 129 GERMANY: BIOSIMULATION MARKET, BY PRODUCT & SERVICE, 2015–2022 (USD MILLION)
Table 130 GERMANY: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 131 GERMANY: BIOSIMULATION SERVICES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 132 GERMANY: BIOSIMULATION MARKET, BY APPLICATION, 2015–2022 (USD MILLION)
Table 133 GERMANY: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2015–2022 (USD MILLION)
Table 134 GERMANY: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2015–2022 (USD MILLION)
Table 135 GERMANY: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2015–2022 (USD MILLION)
Table 136 GERMANY: BIOSIMULATION MARKET, BY DELIVERY MODEL, 2015–2022 (USD MILLION)
Table 137 GERMANY: BIOSIMULATION MARKET, BY END USER, 2015–2022 (USD MILLION)
Table 138 UK: BIOSIMULATION MARKET, BY PRODUCT & SERVICE, 2015–2022 (USD MILLION)
Table 139 UK: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 140 UK: BIOSIMULATION SERVICES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 141 UK: BIOSIMULATION MARKET, BY APPLICATION, 2015–2022 (USD MILLION)
Table 142 UK: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2015–2022 (USD MILLION)
Table 143 UK: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2015–2022 (USD MILLION)
Table 144 UK: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2015–2022 (USD MILLION)
Table 145 UK: BIOSIMULATION MARKET, BY DELIVERY MODEL, 2015–2022 (USD MILLION)
Table 146 UK: BIOSIMULATION MARKET, BY END USER, 2015–2022 (USD MILLION)
Table 147 FRANCE: BIOSIMULATION MARKET, BY PRODUCT & SERVICE, 2015–2022 (USD MILLION)
Table 148 FRANCE: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 149 FRANCE: BIOSIMULATION SERVICES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 150 FRANCE: BIOSIMULATION MARKET, BY APPLICATION, 2015–2022 (USD MILLION)
Table 151 FRANCE: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2015–2022 (USD MILLION)
Table 152 FRANCE: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2015–2022 (USD MILLION)
Table 153 FRANCE: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2015–2022 (USD MILLION)
Table 154 FRANCE: BIOSIMULATION MARKET, BY DELIVERY MODEL, 2015–2022 (USD MILLION)
Table 155 FRANCE: BIOSIMULATION MARKET, BY END USER, 2015–2022 (USD MILLION)
Table 156 ROE: BIOSIMULATION MARKET, BY PRODUCT & SERVICE, 2015–2022 (USD MILLION)
Table 157 ROE: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 158 ROE: BIOSIMULATION SERVICES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 159 ROE: BIOSIMULATION MARKET, BY APPLICATION, 2015–2022 (USD MILLION)
Table 160 ROE: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2015–2022 (USD MILLION)
Table 161 ROE: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2015–2022 (USD MILLION)
Table 162 ROE: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2015–2022 (USD MILLION)
Table 163 ROE: BIOSIMULATION MARKET, BY DELIVERY MODEL, 2015–2022 (USD MILLION)
Table 164 ROE: BIOSIMULATION MARKET, BY END USER, 2015–2022 (USD MILLION)
Table 165 ASIA: BIOSIMULATION MARKET, BY PRODUCT & SERVICE, 2015–2022 (USD MILLION)
Table 166 ASIA: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 167 ASIA: BIOSIMULATION SERVICES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 168 ASIA: BIOSIMULATION MARKET, BY APPLICATION, 2015–2022 (USD MILLION)
Table 169 ASIA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2015–2022 (USD MILLION)
Table 170 ASIA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2015–2022 (USD MILLION)
Table 171 ASIA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2015–2022 (USD MILLION)
Table 172 ASIA: BIOSIMULATION MARKET, BY DELIVERY MODEL, 2015–2022 (USD MILLION)
Table 173 ASIA: BIOSIMULATION MARKET, BY END USER, 2015–2022 (USD MILLION)
Table 174 ROW: BIOSIMULATION MARKET, BY PRODUCT & SERVICE, 2015–2022 (USD MILLION)
Table 175 ROW: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 176 ROW: BIOSIMULATION SERVICES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 177 ROW: BIOSIMULATION MARKET, BY APPLICATION, 2015–2022 (USD MILLION)
Table 178 ROW: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2015–2022 (USD MILLION)
Table 179 ROW: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2015–2022 (USD MILLION)
Table 180 ROW: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2015–2022 (USD MILLION)
Table 181 ROW: BIOSIMULATION MARKET, BY DELIVERY MODEL, 2015–2022 (USD MILLION)
Table 182 ROW: BIOSIMULATION MARKET, BY END USER, 2015–2022 (USD MILLION)
Table 183 RANK OF COMPANIES IN THE GLOBAL BIOSIMULATION MARKET, 2016
Table 184 PRODUCT LAUNCHES AND APPROVALS
Table 185 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
Table 186 ACQUISITIONS
Table 187 EXPANSIONS
Table 1 BIOSIMULATION MARKET, BY PRODUCT & SERVICE, 2015–2022 (USD MILLION)
Table 2 BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 3 BIOSIMULATION SOFTWARE MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 4 NORTH AMERICA: BIOSIMULATION SOFTWARE MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 5 EUROPE: BIOSIMULATION SOFTWARE MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 6 PK/PD MODELING AND SIMULATION SOFTWARE MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 7 NORTH AMERICA: PK/PD MODELING AND SIMULATION SOFTWARE MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 8 EUROPE: PK/PD MODELING AND SIMULATION SOFTWARE MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 9 MOLECULAR MODELING AND SIMULATION SOFTWARE MARKET, BY REGION, 2015–2022 (USD MILLION
Table 10 NORTH AMERICA: MOLECULAR MODELING AND SIMULATION SOFTWARE MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 11 EUROPE: MOLECULAR MODELING AND SIMULATION SOFTWARE MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 12 PBPK MODELING AND SIMULATION SOFTWARE MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 13 NORTH AMERICA: PBPK MODELING AND SIMULATION SOFTWARE MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 14 EUROPE: PBPK MODELING AND SIMULATION SOFTWARE MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 15 TOXICITY PREDICTION SOFTWARE MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 16 NORTH AMERICA: TOXICITY PREDICTION SOFTWARE MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 17 EUROPE: TOXICITY PREDICTION SOFTWARE MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 18 TRIAL DESIGN SOFTWARE MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 19 NORTH AMERICA: TRIAL DESIGN SOFTWARE MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 20 EUROPE: TRIAL DESIGN SOFTWARE MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 21 OTHER BIOSIMULATION SOFTWARE MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 22 NORTH AMERICA: OTHER BIOSIMULATION SOFTWARE MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 23 EUROPE: OTHER BIOSIMULATION SOFTWARE MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 24 BIOSIMULATION SERVICES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 25 BIOSIMULATION SERVICES MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 26 NORTH AMERICA: BIOSIMULATION SERVICES MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 27 EUROPE: BIOSIMULATION SERVICES MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 28 IN-HOUSE BIOSIMULATION SERVICES MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 29 NORTH AMERICA: IN-HOUSE BIOSIMULATION SERVICES MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 30 EUROPE: IN-HOUSE BIOSIMULATION SERVICES MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 31 CONTRACT BIOSIMULATION SERVICES MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 32 NORTH AMERICA: CONTRACT BIOSIMULATION SERVICES MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 33 EUROPE: CONTRACT BIOSIMULATION SERVICES MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 34 BIOSIMULATION MARKET, BY APPLICATION, 2015–2022 (USD MILLION)
Table 35 BIOSIMULATION MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2015–2022 (USD MILLION)
Table 36 BIOSIMULATION MARKET FOR DRUG DEVELOPMENT, BY REGION, 2015–2022 (USD MILLION)
Table 37 NORTH AMERICA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT, BY COUNTRY, 2015–2022 (USD MILLION)
Table 38 EUROPE: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT, BY COUNTRY, 2015–2022 (USD MILLION)
Table 39 BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2015–2022 (USD MILLION)
Table 40 BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY REGION, 2015–2022 (USD MILLION )
Table 41 NORTH AMERICA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY COUNTRY, 2015–2022 (USD MILLION)
Table 42 EUROPE: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY COUNTRY, 2015–2022 (USD MILLION)
Table 43 BIOSIMULATION MARKET FOR PK/PD, BY REGION, 2015–2022 (USD MILLION)
Table 44 NORTH AMERICA: BIOSIMULATION MARKET FOR PK/PD, BY COUNTRY, 2015–2022 (USD MILLION)
Table 45 EUROPE: BIOSIMULATION MARKET FOR PK/PD, BY COUNTRY, 2015–2022 (USD MILLION)
Table 46 BIOSIMULATION MARKET FOR ADME/TOX, BY REGION, 2015–2022 (USD MILLION)
Table 47 NORTH AMERICA: BIOSIMULATION MARKET FOR ADME/TOX, BY COUNTRY, 2015–2022 (USD MILLION)
Table 48 EUROPE: BIOSIMULATION MARKET FOR ADME/TOX, BY COUNTRY, 2015–2022 (USD MILLION)
Table 49 BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY REGION, 2015–2022 (USD MILLION)
Table 50 NORTH AMERICA: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 51 EUROPE: BIOSIMULATION MARKET FOR CLINICAL TRIALS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 52 BIOSIMULATION MARKET FOR DRUG DISCOVERY, BY TYPE, 2015–2022 (USD MILLION )
Table 53 BIOSIMULATION MARKET FOR DRUG DISCOVERY, BY REGION, 2015–2022 (USD MILLION)
Table 54 NORTH AMERICA: BIOSIMULATION MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2015–2022 (USD MILLION)
Table 55 EUROPE: BIOSIMULATION MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2015–2022 (USD MILLION)
Table 56 BIOSIMULATION MARKET FOR TARGET IDENTIFICATION AND OPTIMIZATION, BY REGION, 2015–2022 (USD MILLION)
Table 57 NORTH AMERICA: BIOSIMULATION MARKET FOR TARGET IDENTIFICATION AND VALIDATION, BY COUNTRY, 2015–2022 (USD MILLION)
Table 58 EUROPE: BIOSIMULATION MARKET FOR TARGET IDENTIFICATION AND VALIDATION, BY COUNTRY, 2015–2022 (USD MILLION)
Table 59 BIOSIMULATION MARKET FOR LEAD IDENTIFICATION AND OPTIMIZATION, BY REGION, 2015–2022 (USD MILLION)
Table 60 NORTH AMERICA: BIOSIMULATION MARKET FOR LEAD IDENTIFICATION AND OPTIMIZATION, BY COUNTRY, 2015–2022 (USD MILLION)
Table 61 EUROPE: BIOSIMULATION MARKET FOR LEAD IDENTIFICATION AND OPTIMIZATION, BY COUNTRY, 2015–2022 (USD MILLION)
Table 62 BIOSIMULATION MARKET FOR OTHER APPLICATIONS, BY REGION, 2015–2022 (USD MILLION )
Table 63 NORTH AMERICA: BIOSIMULATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 64 EUROPE: BIOSIMULATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 65 GLOBAL BIOSIMULATION MARKET, BY DELIVERY MODEL, 2015–2022 (USD MILLION)
Table 66 GLOBAL BIOSIMULATION MARKET FOR SUBSCRIPTION MODELS, BY REGION, 2015–2022 (USD MILLION)
Table 67 NORTH AMERICA: BIOSIMULATION MARKET FOR SUBSCRIPTION MODELS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 68 EUROPE: BIOSIMULATION MARKET FOR SUBSCRIPTION MODELS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 69 GLOBAL BIOSIMULATION MARKET FOR OWNERSHIP MODELS, BY REGION, 2015–2022 (USD MILLION)
Table 70 NORTH AMERICA: BIOSIMULATION MARKET FOR OWNERSHIP MODELS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 71 EUROPE: BIOSIMULATION MARKET FOR OWNERSHIP MODELS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 72 BIOSIMULATION MARKET, BY END USER, 2015–2022 (USD MILLION)
Table 73 BIOSIMULATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2015–2022 (USD MILLION)
Table 74 NORTH AMERICA: BIOSIMULATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2015–2022 (USD MILLION)
Table 75 EUROPE: BIOSIMULATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2015–2022 (USD MILLION)
Table 76 BIOSIMULATION MARKET FOR RESEARCH INSTITUTES, BY REGION, 2015–2022 (USD MILLION)
Table 77 NORTH AMERICA: BIOSIMULATION MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2015–2022 (USD MILLION)
Table 78 EUROPE: BIOSIMULATION MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2015–2022 (USD MILLION)
Table 79 BIOSIMULATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2015–2022 (USD MILLION)
Table 80 NORTH AMERICA: BIOSIMULATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 81 EUROPE: BIOSIMULATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 82 BIOSIMULATION MARKET FOR REGULATORY AUTHORITIES, BY REGION, 2015–2022 (USD MILLION)
Table 83 NORTH AMERICA: BIOSIMULATION MARKET FOR REGULATORY AUTHORITIES, BY COUNTRY, 2015–2022 (USD MILLION)
Table 84 EUROPE: BIOSIMULATION MARKET FOR REGULATORY AUTHORITIES, BY COUNTRY, 2015–2022 (USD MILLION)
Table 85 BIOSIMULATION MARKET FOR OTHER END USERS, BY REGION, 2015–2022 (USD MILLION)
Table 86 NORTH AMERICA: BIOSIMULATION MARKET FOR OTHER END USERS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 87 EUROPE: BIOSIMULATION MARKET FOR OTHER END USERS, BY COUNTRY, 2015–2022 (USD MILLION)
Table 88 BIOSIMULATION MARKET, BY REGION, 2015–2022 (USD MILLION)
Table 89 NORTH AMERICA BIOSIMULATION MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 90 NORTH AMERICA: BIOSIMULATION MARKET, BY PRODUCT & SERVICE, 2015–2022 (USD MILLION)
Table 91 NORTH AMERICA: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 92 NORTH AMERICA: BIOSIMULATION SERVICES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 93 NORTH AMERICA: BIOSIMULATION MARKET, BY APPLICATION, 2015–2022 (USD MILLION)
Table 94 NORTH AMERICA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2015–2022 (USD MILLION)
Table 95 NORTH AMERICA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2015–2022 (USD MILLION)
Table 96 NORTH AMERICA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2015–2022 (USD MILLION)
Table 97 NORTH AMERICA: BIOSIMULATION MARKET, BY DELIVERY MODEL, 2015–2022 (USD MILLION)
Table 98 NORTH AMERICA: BIOSIMULATION MARKET, BY END USER, 2015–2022 (USD MILLION)
Table 99 US: BIOSIMULATION MARKET, BY PRODUCT & SERVICE, 2015–2022 (USD MILLION)
Table 100 US: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 101 US: BIOSIMULATION SERVICES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 102 US: BIOSIMULATION MARKET, BY APPLICATION, 2015–2022 (USD MILLION)
Table 103 US: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2015–2022 (USD MILLION)
Table 104 US: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2015–2022 (USD MILLION)
Table 105 US: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2015–2022 (USD MILLION)
Table 106 US: BIOSIMULATION MARKET, BY DELIVERY MODEL, 2015–2022 (USD MILLION)
Table 107 US: BIOSIMULATION MARKET, BY END USER, 2015–2022 (USD MILLION)
Table 108 CANADA: BIOSIMULATION MARKET, BY PRODUCT & SERVICE, 2015–2022 (USD MILLION)
Table 109 CANADA: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 110 CANADA: BIOSIMULATION SERVICES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 111 CANADA: BIOSIMULATION MARKET, BY APPLICATION, 2015–2022 (USD MILLION)
Table 112 CANADA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2015–2022 (USD MILLION)
Table 113 CANADA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2015–2022 (USD MILLION)
Table 114 CANADA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2015–2022 (USD MILLION)
Table 115 CANADA: BIOSIMULATION MARKET, BY DELIVERY MODEL, 2015–2022 (USD MILLION)
Table 116 CANADA: BIOSIMULATION MARKET, BY END USER, 2015–2022 (USD MILLION)
Table 117 EUROPE: PHARMACEUTICAL R&D EXPENDITURE, BY COUNTRY, 2015
Table 118 EUROPE: BIOSIMULATION MARKET, BY COUNTRY, 2015–2022 (USD MILLION)
Table 119 EUROPE: BIOSIMULATION MARKET, BY PRODUCT & SERVICE, 2015–2022 (USD MILLION)
Table 120 EUROPE: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 121 EUROPE: BIOSIMULATION SERVICES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 122 EUROPE: BIOSIMULATION MARKET, BY APPLICATION, 2015–2022 (USD MILLION)
Table 123 EUROPE: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2015–2022 (USD MILLION)
Table 124 EUROPE: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2015–2022 (USD MILLION)
Table 125 EUROPE: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2015–2022 (USD MILLION)
Table 126 EUROPE: BIOSIMULATION MARKET, BY DELIVERY MODEL, 2015–2022 (USD MILLION)
Table 127 EUROPE: BIOSIMULATION MARKET, BY END USER, 2015–2022 (USD MILLION)
Table 128 BIOTECHNOLOGY INDUSTRY IN GERMANY (2009 VS. 2016)
Table 129 GERMANY: BIOSIMULATION MARKET, BY PRODUCT & SERVICE, 2015–2022 (USD MILLION)
Table 130 GERMANY: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 131 GERMANY: BIOSIMULATION SERVICES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 132 GERMANY: BIOSIMULATION MARKET, BY APPLICATION, 2015–2022 (USD MILLION)
Table 133 GERMANY: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2015–2022 (USD MILLION)
Table 134 GERMANY: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2015–2022 (USD MILLION)
Table 135 GERMANY: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2015–2022 (USD MILLION)
Table 136 GERMANY: BIOSIMULATION MARKET, BY DELIVERY MODEL, 2015–2022 (USD MILLION)
Table 137 GERMANY: BIOSIMULATION MARKET, BY END USER, 2015–2022 (USD MILLION)
Table 138 UK: BIOSIMULATION MARKET, BY PRODUCT & SERVICE, 2015–2022 (USD MILLION)
Table 139 UK: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 140 UK: BIOSIMULATION SERVICES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 141 UK: BIOSIMULATION MARKET, BY APPLICATION, 2015–2022 (USD MILLION)
Table 142 UK: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2015–2022 (USD MILLION)
Table 143 UK: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2015–2022 (USD MILLION)
Table 144 UK: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2015–2022 (USD MILLION)
Table 145 UK: BIOSIMULATION MARKET, BY DELIVERY MODEL, 2015–2022 (USD MILLION)
Table 146 UK: BIOSIMULATION MARKET, BY END USER, 2015–2022 (USD MILLION)
Table 147 FRANCE: BIOSIMULATION MARKET, BY PRODUCT & SERVICE, 2015–2022 (USD MILLION)
Table 148 FRANCE: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 149 FRANCE: BIOSIMULATION SERVICES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 150 FRANCE: BIOSIMULATION MARKET, BY APPLICATION, 2015–2022 (USD MILLION)
Table 151 FRANCE: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2015–2022 (USD MILLION)
Table 152 FRANCE: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2015–2022 (USD MILLION)
Table 153 FRANCE: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2015–2022 (USD MILLION)
Table 154 FRANCE: BIOSIMULATION MARKET, BY DELIVERY MODEL, 2015–2022 (USD MILLION)
Table 155 FRANCE: BIOSIMULATION MARKET, BY END USER, 2015–2022 (USD MILLION)
Table 156 ROE: BIOSIMULATION MARKET, BY PRODUCT & SERVICE, 2015–2022 (USD MILLION)
Table 157 ROE: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 158 ROE: BIOSIMULATION SERVICES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 159 ROE: BIOSIMULATION MARKET, BY APPLICATION, 2015–2022 (USD MILLION)
Table 160 ROE: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2015–2022 (USD MILLION)
Table 161 ROE: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2015–2022 (USD MILLION)
Table 162 ROE: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2015–2022 (USD MILLION)
Table 163 ROE: BIOSIMULATION MARKET, BY DELIVERY MODEL, 2015–2022 (USD MILLION)
Table 164 ROE: BIOSIMULATION MARKET, BY END USER, 2015–2022 (USD MILLION)
Table 165 ASIA: BIOSIMULATION MARKET, BY PRODUCT & SERVICE, 2015–2022 (USD MILLION)
Table 166 ASIA: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 167 ASIA: BIOSIMULATION SERVICES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 168 ASIA: BIOSIMULATION MARKET, BY APPLICATION, 2015–2022 (USD MILLION)
Table 169 ASIA: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2015–2022 (USD MILLION)
Table 170 ASIA: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2015–2022 (USD MILLION)
Table 171 ASIA: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2015–2022 (USD MILLION)
Table 172 ASIA: BIOSIMULATION MARKET, BY DELIVERY MODEL, 2015–2022 (USD MILLION)
Table 173 ASIA: BIOSIMULATION MARKET, BY END USER, 2015–2022 (USD MILLION)
Table 174 ROW: BIOSIMULATION MARKET, BY PRODUCT & SERVICE, 2015–2022 (USD MILLION)
Table 175 ROW: BIOSIMULATION SOFTWARE MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 176 ROW: BIOSIMULATION SERVICES MARKET, BY TYPE, 2015–2022 (USD MILLION)
Table 177 ROW: BIOSIMULATION MARKET, BY APPLICATION, 2015–2022 (USD MILLION)
Table 178 ROW: BIOSIMULATION MARKET FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2015–2022 (USD MILLION)
Table 179 ROW: BIOSIMULATION MARKET FOR PRECLINICAL TESTING, BY TYPE, 2015–2022 (USD MILLION)
Table 180 ROW: BIOSIMULATION MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2015–2022 (USD MILLION)
Table 181 ROW: BIOSIMULATION MARKET, BY DELIVERY MODEL, 2015–2022 (USD MILLION)
Table 182 ROW: BIOSIMULATION MARKET, BY END USER, 2015–2022 (USD MILLION)
Table 183 RANK OF COMPANIES IN THE GLOBAL BIOSIMULATION MARKET, 2016
Table 184 PRODUCT LAUNCHES AND APPROVALS
Table 185 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
Table 186 ACQUISITIONS
Table 187 EXPANSIONS
LIST OF FIGURES
Figure 1 RESEARCH DESIGN: BIOSIMULATION MARKET
Figure 2 BREAK DOWN OF PRIMARY INTERVIEWS: BY COMPANY, DESIGNATION, AND REGION
Figure 3 MARKET ESTIMATION: BOTTOM-UP APPROACH
Figure 4 GLOBAL MARKET SIZE OF THE BIOSIMULATION MARKET: TOP-DOWN APPROACH
Figure 5 DATA TRIANGULATION METHODOLOGY
Figure 6 BIOSIMULATION SOFTWARE TO DOMINATE THE BIOSIMULATION MARKET IN 2017 AND 2022
Figure 7 DRUG DEVELOPMENT SEGMENT TO DOMINATE THE BIOSIMULATION APPLICATIONS MARKET IN 2017 AND 2022
Figure 8 SUBSCRIPTION MODEL SEGMENT TO DOMINATE THE DELIVERY MODEL SEGMENT OF BIOSIMULATION MARKET IN 2017 AND 2022
Figure 9 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE THE BIOSIMULATION END-USER MARKET
Figure 10 EUROPE TO WITNESS HIGH GROWTH DURING THE FORECAST PERIOD (2017–2022)
Figure 11 INCREASE IN R&D INVESTMENTS IN THE PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES TO DRIVE THE GROWTH OF THE MARKET
Figure 12 PK/PD MODELING AND SIMULATION SOFTWARE TO ACCOUNT FOR THE LARGEST MARKET SIZE IN 2017 AND 2022
Figure 13 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO ACCOUNT FOR THE LARGEST SHARE OF THE BIOSIMULATION MARKET IN EUROPE IN 2017
Figure 14 PRECLINICAL TESTING TO WITNESS HIGH GROWTH FROM 2017 TO 2022
Figure 15 BIOSIMULATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
Figure 16 SOFTWARE SEGMENT TO DOMINATE THE BIOSIMULATION MARKET IN 2017
Figure 17 DRUG DEVELOPMENT SEGMENT TO DOMINATE THE BIOSIMULATION MARKET DURING THE FORECAST PERIOD
Figure 18 OWNERSHIP MODELS SEGMENT TO OFFER SIGNIFICANT GROWTH OPPORTUNITIES DURING THE FORECAST PERIOD
Figure 19 BIOSIMULATION MARKET, BY END USER, 2017 VS. 2022 (USD MILLION)
Figure 20 BIOSIMULATION MARKET IN EUROPE TO WITNESS THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
Figure 21 NORTH AMERICA: BIOSIMULATION MARKET SNAPSHOT
Figure 22 EUROPE: BIOSIMULATION MARKET SNAPSHOT
Figure 23 ASIA: BIOSIMULATION MARKET SNAPSHOT
Figure 24 ROW: BIOSIMULATION MARKET SNAPSHOT
Figure 25 MARKET EVOLUTION FRAMEWORK
Figure 26 SIMULATION PLUS: COMPANY SNAPSHOT (2016)
Figure 27 DASSAULT SYST?MES: COMPANY SNAPSHOT (2016)
Figure 28 PHYSIOMICS: COMPANY SNAPSHOT (2017)
Figure 1 RESEARCH DESIGN: BIOSIMULATION MARKET
Figure 2 BREAK DOWN OF PRIMARY INTERVIEWS: BY COMPANY, DESIGNATION, AND REGION
Figure 3 MARKET ESTIMATION: BOTTOM-UP APPROACH
Figure 4 GLOBAL MARKET SIZE OF THE BIOSIMULATION MARKET: TOP-DOWN APPROACH
Figure 5 DATA TRIANGULATION METHODOLOGY
Figure 6 BIOSIMULATION SOFTWARE TO DOMINATE THE BIOSIMULATION MARKET IN 2017 AND 2022
Figure 7 DRUG DEVELOPMENT SEGMENT TO DOMINATE THE BIOSIMULATION APPLICATIONS MARKET IN 2017 AND 2022
Figure 8 SUBSCRIPTION MODEL SEGMENT TO DOMINATE THE DELIVERY MODEL SEGMENT OF BIOSIMULATION MARKET IN 2017 AND 2022
Figure 9 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE THE BIOSIMULATION END-USER MARKET
Figure 10 EUROPE TO WITNESS HIGH GROWTH DURING THE FORECAST PERIOD (2017–2022)
Figure 11 INCREASE IN R&D INVESTMENTS IN THE PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES TO DRIVE THE GROWTH OF THE MARKET
Figure 12 PK/PD MODELING AND SIMULATION SOFTWARE TO ACCOUNT FOR THE LARGEST MARKET SIZE IN 2017 AND 2022
Figure 13 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO ACCOUNT FOR THE LARGEST SHARE OF THE BIOSIMULATION MARKET IN EUROPE IN 2017
Figure 14 PRECLINICAL TESTING TO WITNESS HIGH GROWTH FROM 2017 TO 2022
Figure 15 BIOSIMULATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
Figure 16 SOFTWARE SEGMENT TO DOMINATE THE BIOSIMULATION MARKET IN 2017
Figure 17 DRUG DEVELOPMENT SEGMENT TO DOMINATE THE BIOSIMULATION MARKET DURING THE FORECAST PERIOD
Figure 18 OWNERSHIP MODELS SEGMENT TO OFFER SIGNIFICANT GROWTH OPPORTUNITIES DURING THE FORECAST PERIOD
Figure 19 BIOSIMULATION MARKET, BY END USER, 2017 VS. 2022 (USD MILLION)
Figure 20 BIOSIMULATION MARKET IN EUROPE TO WITNESS THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
Figure 21 NORTH AMERICA: BIOSIMULATION MARKET SNAPSHOT
Figure 22 EUROPE: BIOSIMULATION MARKET SNAPSHOT
Figure 23 ASIA: BIOSIMULATION MARKET SNAPSHOT
Figure 24 ROW: BIOSIMULATION MARKET SNAPSHOT
Figure 25 MARKET EVOLUTION FRAMEWORK
Figure 26 SIMULATION PLUS: COMPANY SNAPSHOT (2016)
Figure 27 DASSAULT SYST?MES: COMPANY SNAPSHOT (2016)
Figure 28 PHYSIOMICS: COMPANY SNAPSHOT (2017)
